Why are GLP-1 medications constantly out of stock at pharmacies?

GLP-1 medication shortages stem from unprecedented demand exceeding manufacturing capacity. When Wegovy and Ozempic gained widespread popularity through social media and celebrity use, demand surged beyond what Novo Nordisk and Eli Lilly anticipated. These are complex biologic medications requiring specialized manufacturing facilities that can't scale up quickly. Each batch requires weeks of production, quality testing, and distribution. Manufacturing disruptions, quality control issues, and supply chain challenges for raw materials compound the problem. Different doses have different availability - higher doses (2.4mg semaglutide, 15mg tirzepatide) often have better availability than starter doses because manufacturers prioritize patients already established on therapy. Shortages vary by region and pharmacy chain. The FDA maintains a drug shortage database, and manufacturers provide availability updates. Most experts expect supply to remain constrained through 2024-2025 until manufacturing capacity expands. Patients can improve their chances by: calling multiple pharmacies, using pharmacy apps to check stock, asking pharmacists about delivery schedules, and considering mail-order options.